Skip to main content

Table 3 Responses on the management of the inflammatory arthritis in patient with a 6-week unplanned pregnancy with conventional synthetic disease modifying anti-rheumatic drugs, biologics/small molecules, and other medications

From: Management of Inflammatory Arthritis in pregnancy: a National Cross-Sectional Survey of Canadian rheumatologists

  Continue drug, continue pregnancy (%) Stop drug, continue pregnancy (%) Continue drug, counsel regarding termination (%) Stop drug, counsel regarding termination (%) Not sure (%)
Conventional synthetic disease modifying anti-rheumatic drugs
 Azathioprine 80.3* 6.1 1.5 4.5 7.6
 Chloroquine 71.2 7.6 3.0 0 18.2
 Cyclophosphamide 0 16.7 13.6 60.6 9.1
 Cyclosporine 27.3 18.2 1.5 19.7 33.3
 Doxycycline 0 29.2 0 6.2 64.6
 Gold salts 30.3 18.2 0 9.1 42.4
 Hydroxychloroquine 90.9* 4.5 1.5 0 3.0
 Leflunomide 0 16.7 6.1 69.7 7.6
 Methotrexate 0 22.7 7.6 65.2 4.5
 Minocycline 0 34.8 0 6.1 69.7
 Mycophenolate mofetil 3.0 19.7 10.6 47.0 19.7
 Sulfasalazine 76.6* 14.1 0 1.6 7.8
Biologics/small molecules
 Abatacept 24.2 45.5 1.5 6.1 22.7
 Adalimumab 66.7 25.8 1.5 1.5 4.5
 Anakinra 15.2 39.4 1.5 4.5 39.4
 Apremilast 4.6 35.4 0 6.2 53.8
 Certolizumab 63.1 26.2 1.5 0 9.2
 Etanercept 69.7 24.2 0 1.5 4.5
 Golimumab 60.6 28.8 1.5 1.5 7.6
 Infliximab 60.0 29.2 1.5 1.5 7.7
 Rituximab 18.2 39.4 1.5 6.1 34.8
 Tocilizumab 18.2 39.4 1.5 4.5 36.4
 Tofacitinib 3.0 31.8 0 7.6 57.6
 Ustekinumab 13.8 33.8 1.5 4.6 46.2
Other medications
 Celecoxib 39 56 0 0 3
 Ibuprofen 64 33 0 0 3
 Naproxen 65 32 0 0 3
 Prednisone 85* 12 0 0 3
  1. *Indicates consensus among respondents based on a priori cut-off of ≥75%